|Articles|March 1, 2023

RoslinCT, Lykan Biosciences Add Six cGMP Suites to Massachusetts Facility

Expansion expected to increase global capacity by 75%.

RoslinCT and Lykan Biosciences, two contract development and manufacturing organizations (CDMOs), are adding six new cGMP processing suites to their facility in Hopkinton, Mass. The new sites bring the companies’ total to 22 overall, with 14 at the aforementioned location and another eight in Edinburgh, UK.

Ranging from 105 to 525 square feet, the new processing suites are designed to meet both US and EU regulatory requirements for clinical and commercial manufacturing. As part of the increase, an automated processing room is included and will reportedly be capable of accommodating a range of manufacturing platforms as well as allogeneic and autologous-based products.

“With this expansion, we will increase our capacity by 75% enabling us to meet the needs of a greater number of projects and their respective volume requirements,” says Patrick Lucy, president and CEO of Lykan Biosciences.


Related to this article

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS). | © Tada Images - stock.adobe.com 521699065
In this week’s Pharma Pulse, the FDA launches a program that lets companies share its approval packages with foreign regulators, UPS agrees to acquire Australia and New Zealand health care courier Smartways Logistics and Cognizant introduces an AI-enabled patient hub offering.